Skip navigation
Efficacy in S. aureus Skin and Bacteremia
Clinically successful against most Gram-positive organisms in complicated skin infections1
Incidence of clinical success* by infecting pathogen in microbiologically evaluable† patients in clinical studies



* Clinical success was defined as cure or clinical improvement, based primarily on the investigator's assessment of clinical response at the Test of Cure (TOC) evaluation, conducted 6 to 20 days after the conclusion of therapy.

† Microbiologically evaluable patients were clinically evaluable and had a confirmed Gram-positive pathogen isolated at baseline.

‡ As determined by central laboratory

§ Vancomycin or semisynthetic penicillins

Proven clinical success of CUBICIN 6 mg/kg once daily in S. aureus bacteremia


  • In a post hoc analysis among 46 patients with S. aureus bacteremia where catheter is a source, clinical success — based solely on efficacy criteria|| — was reported in 92% of patients treated with CUBICIN vs 81% of patients treated with comparators2

CI=confidence interval.

*Patients in the comparator treatment arm were to receive vancomycin + 4 days of initial low-dose gentamicin or a semisynthetic penicillin + 4 days of initial low-dose gentamicin. (95% CI for the difference in success rates [CUBICIN – comparator]; intent-to-treat population).

† Patients in the MRSA subgroup of the comparator treatment arm were to receive vancomycin + 4 days of initial low-dose gentamicin; however, 1 patient received a semisynthetic penicillin instead of vancomycin + 4 days of initial low-dose gentamicin. Four patients received vancomycin alone. (97.5% CI for the difference in success rates [CUBICIN – comparator; adjusted for multiplicity]; intent-to-treat population).

‡ Patients in the MSSA subgroup of the comparator treatment arm were to receive a semisynthetic penicillin + 4 days of initial low-dose gentamicin; however, 10 patients received vancomycin instead of a semisynthetic penicillin + 4 days of initial low-dose gentamicin. Three patients received semisynthetic penicillin alone. (97.5% CI for the difference in success rates [CUBICIN – comparator; adjusted for multiplicity]; intent-to-treat population).

§ The MRSA subgroup was prespecified in the protocol.

|| Only patients with persisting/relapsing S. aureus infection, death, or clinical failure at the Test of Cure visit 6 weeks after the end of therapy were considered failures in this analysis, which differs from the definition of clinical failure in the overall study.

References: 1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2004;38:1673-1681. 2. Boucher H, Corey G, Filler S, Parsonnet J, Campion M, Fowler V. Appropriateness of two-week therapy for catheter-related (cath-rel) S. aureus bacteremia (SAB). Poster presented at: the 46th Annual ICAAC Meeting; September 27-30, 2006; San Francisco, Calif. Poster L-1204.